Revenue (Disaggregation of Revenue by Product) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Revenue	$ 9,498,600,000	$ 6,941,600,000	$ 24,770,700,000	$ 21,239,600,000
U.S.
Disaggregation of Revenue [Line Items]
Revenue	5,368,100,000	4,422,100,000	15,335,600,000	13,531,500,000
Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	4,130,500,000	2,519,400,000	9,435,000,000	7,708,100,000
Diabetes
Disaggregation of Revenue [Line Items]
Revenue	4,720,400,000	3,662,600,000	13,921,600,000	10,489,000,000
Diabetes \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	3,460,000,000	2,488,600,000	10,316,400,000	7,057,300,000
Diabetes \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	1,260,300,000	1,174,000,000	3,605,200,000	3,431,600,000
Trulicity®
Disaggregation of Revenue [Line Items]
Revenue	1,673,600,000	1,850,400,000	5,463,200,000	5,503,500,000
Trulicity® \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	1,259,000,000	1,418,300,000	4,177,700,000	4,162,400,000
Trulicity® \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	414,600,000	432,000,000.0	1,285,600,000	1,341,100,000
Mounjaro®
Disaggregation of Revenue [Line Items]
Revenue	1,409,300,000	187,300,000	2,957,500,000	203,200,000
Mounjaro® \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	1,277,000,000	97,300,000	2,729,100,000	109,900,000
Mounjaro® \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	132,400,000	90,000,000.0	228,400,000	93,300,000
Jardiance
Disaggregation of Revenue [Line Items]
Revenue	700,800,000	573,300,000	1,946,600,000	1,453,700,000
Jardiance \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	415,900,000	350,900,000	1,131,500,000	831,400,000
Jardiance \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	284,800,000	222,400,000	815,100,000	622,400,000
Humalog®
Disaggregation of Revenue [Line Items]
Revenue	395,400,000	447,000,000.0	1,296,800,000	1,512,300,000
Humalog® \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	194,200,000	248,100,000	695,600,000	855,800,000
Humalog® \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	201,200,000	198,800,000	601,200,000	656,400,000
Humulin®
Disaggregation of Revenue [Line Items]
Revenue	206,700,000	238,200,000	664,000,000.0	785,400,000
Humulin® \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	145,500,000	169,500,000	488,600,000	562,300,000
Humulin® \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	61,200,000	68,700,000	175,400,000	223,100,000
Basaglar®
Disaggregation of Revenue [Line Items]
Revenue	179,600,000	193,000,000.0	543,100,000	558,700,000
Basaglar® \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	111,400,000	124,800,000	329,700,000	339,900,000
Basaglar® \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	68,200,000	68,100,000	213,400,000	218,800,000
Baqsimi
Disaggregation of Revenue [Line Items]
Revenue	13,100,000	43,000,000.0	658,400,000	101,200,000
Baqsimi \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	3,800,000	35,200,000	633,100,000	79,500,000
Baqsimi \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	9,300,000	7,800,000	25,400,000	21,700,000
Other diabetes
Disaggregation of Revenue [Line Items]
Revenue	141,900,000	130,400,000	392,000,000.0	371,000,000.0
Other diabetes \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	53,200,000	44,500,000	131,100,000	116,100,000
Other diabetes \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	88,600,000	86,200,000	260,700,000	254,800,000
Oncology
Disaggregation of Revenue [Line Items]
Revenue	1,747,100,000	1,293,300,000	4,774,100,000	4,015,000,000
Oncology \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	1,001,600,000	732,700,000	2,690,000,000	2,335,400,000
Oncology \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	745,500,000	560,600,000	2,084,100,000	1,679,600,000
Verzenio®
Disaggregation of Revenue [Line Items]
Revenue	1,040,200,000	617,700,000	2,717,900,000	1,675,600,000
Verzenio® \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	684,600,000	414,800,000	1,734,200,000	1,100,500,000
Verzenio® \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	355,700,000	202,900,000	983,700,000	575,100,000
Cyramza®
Disaggregation of Revenue [Line Items]
Revenue	224,100,000	232,100,000	721,100,000	693,600,000
Cyramza® \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	88,000,000.0	87,500,000	303,600,000	259,300,000
Cyramza® \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	136,100,000	144,600,000	417,500,000	434,300,000
Erbitux®
Disaggregation of Revenue [Line Items]
Revenue	153,900,000	144,900,000	446,300,000	408,300,000
Erbitux® \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	134,000,000.0	126,300,000	398,300,000	361,000,000.0
Erbitux® \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	19,900,000	18,700,000	48,000,000.0	47,400,000
Alimta®
Disaggregation of Revenue [Line Items]
Revenue	53,500,000	119,400,000	172,600,000	691,100,000
Alimta® \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	21,200,000	64,600,000	59,200,000	490,500,000
Alimta® \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	32,300,000	54,800,000	113,500,000	200,500,000
Other oncology
Disaggregation of Revenue [Line Items]
Revenue	275,400,000	179,200,000	716,200,000	546,400,000
Other oncology \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	73,800,000	39,500,000	194,700,000	124,100,000
Other oncology \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	201,500,000	139,600,000	521,400,000	422,300,000
Immunology
Disaggregation of Revenue [Line Items]
Revenue	986,900,000	866,400,000	2,693,200,000	2,411,000,000
Immunology \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	575,000,000.0	516,700,000	1,452,600,000	1,317,300,000
Immunology \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	412,000,000.0	349,700,000	1,240,600,000	1,093,800,000
Taltz®
Disaggregation of Revenue [Line Items]
Revenue	744,200,000	679,900,000	1,975,000,000	1,774,200,000
Taltz® \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	509,300,000	493,800,000	1,293,800,000	1,212,600,000
Taltz® \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	234,900,000	186,100,000	681,200,000	561,600,000
Olumiant®
Disaggregation of Revenue [Line Items]
Revenue	231,400,000	182,900,000	679,200,000	624,700,000
Olumiant® \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	65,700,000	22,900,000	158,800,000	104,600,000
Olumiant® \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	165,700,000	160,000,000.0	520,400,000	520,100,000
Other immunology
Disaggregation of Revenue [Line Items]
Revenue	11,400,000	3,600,000	39,000,000.0	12,100,000
Other immunology \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	0	0	0	100,000
Other immunology \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	11,400,000	3,600,000	39,000,000.0	12,100,000
Neuroscience
Disaggregation of Revenue [Line Items]
Revenue	1,768,100,000	373,200,000	2,515,800,000	1,160,900,000
Neuroscience \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	207,400,000	145,800,000	512,800,000	444,000,000.0
Neuroscience \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	1,560,600,000	227,400,000	2,003,000,000	716,900,000
Zyprexa
Disaggregation of Revenue [Line Items]
Revenue	1,481,400,000	81,400,000	1,651,000,000	261,700,000
Zyprexa \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	49,900,000	8,000,000.0	69,100,000	26,200,000
Zyprexa \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	1,431,500,000	73,400,000	1,581,900,000	235,500,000
Emgality®
Disaggregation of Revenue [Line Items]
Revenue	168,500,000	168,500,000	492,200,000	475,200,000
Emgality® \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	126,500,000	114,000,000.0	354,000,000.0	330,800,000
Emgality® \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	42,100,000	54,600,000	138,200,000	144,400,000
Other neuroscience
Disaggregation of Revenue [Line Items]
Revenue	118,200,000	123,300,000	372,600,000	424,000,000.0
Other neuroscience \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	31,000,000.0	23,800,000	89,700,000	87,000,000.0
Other neuroscience \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	87,000,000.0	99,400,000	282,900,000	337,000,000.0
Other
Disaggregation of Revenue [Line Items]
Revenue	276,100,000	746,000,000.0	866,000,000.0	3,163,700,000
Other \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	124,100,000	538,300,000	363,800,000	2,377,500,000
Other \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	152,000,000.0	207,800,000	502,100,000	786,200,000
Forteo®
Disaggregation of Revenue [Line Items]
Revenue	146,400,000	177,100,000	416,800,000	453,000,000.0
Forteo® \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	101,200,000	112,700,000	269,200,000	261,400,000
Forteo® \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	45,200,000	64,400,000	147,600,000	191,700,000
Cialis®
Disaggregation of Revenue [Line Items]
Revenue	86,800,000	115,700,000	302,700,000	480,400,000
Cialis® \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	4,900,000	8,100,000	21,600,000	25,800,000
Cialis® \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	82,000,000.0	107,700,000	281,100,000	454,700,000
COVID-19 antibodies
Disaggregation of Revenue [Line Items]
Revenue	0	386,600,000	0	1,985,500,000
COVID-19 antibodies \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	0	386,600,000	0	1,970,900,000
COVID-19 antibodies \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	0	0	0	14,700,000
Other
Disaggregation of Revenue [Line Items]
Revenue	42,900,000	66,600,000	146,500,000	244,800,000
Other \| U.S.
Disaggregation of Revenue [Line Items]
Revenue	18,000,000.0	30,900,000	73,000,000.0	119,400,000
Other \| Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	$ 24,800,000	$ 35,700,000	$ 73,400,000	$ 125,100,000